# Retatrutide vs Orforglipron: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron

Last updated: 2026-10-12

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Retatrutide vs Orforglipron

Compared side by side

# Retatrutide vs orforglipron: how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Orforglipron acts on one receptor, GLP-1, and is a small molecule (not a peptide) taken as a daily tablet; retatrutide is a weekly shot that activates three, GLP-1, GIP and glucagon. Orforglipron is FDA-approved, as Foundayo since April 2026, and retatrutide isn’t approved yet. In their own trials, orforglipron’s top dose averaged about 11% weight loss at 72 weeks, and retatrutide’s top dose about 25–28% at 80 weeks in phase 3.

## Side by side

| Compared | [Retatrutide](https://pepvault.app/peptides/retatrutide) | [Orforglipron](https://pepvault.app/peptides/orforglipron) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | LY3437943 | Foundayo, LY3502970, Orfo |
| What it is | The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). | A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management. |
| How it works | Triple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one. | Small-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily. |
| Commonly reported | Appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet. | The easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial. |
| Studied range | Research range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation. | FDA label: 0.8–17.2 mg, starting dose 0.8 mg. |
| How often | Weekly | Daily |
| Half-life | ~6 days (measured in early trials in people) | ~29–49 hours (FDA label; steady levels after about a week of daily tablets) |
| Route | SubQ injection | Oral tablet |
| Typical run | Phase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration. | FDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain | Nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking retatrutide or orforglipron? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Retatrutide

- Day 1–28 · 2 mg Triple-agonist is kicking in
- Day 29–84 · 4 mg Dose-response steepens
- Day 60+ · 9 mg Watch for dysesthesia at higher doses
- Day 84+ This is a maintenance medication, not a course
- Day 85–168 · 8 mg Higher steps: strong satiety
- Day 169–336 No plateau yet at week 48
- Day 337–476 Phase 3 territory: the headline numbers

[Every card for retatrutide, with its sources](https://pepvault.app/peptides/retatrutide#weeks)

### Orforglipron

- Day 1–30 · 0.8 mg The 0.8 mg start
- Day 31–60 · 2.5 mg 2.5 mg, the second step
- Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
- Day 91+ · 9 mg 9 mg, an optional step
- Day 121+ · 14.5 mg 14.5 mg, the step before the top
- Day 151+ · 17.2 mg 17.2 mg, the top dose

[Every card for orforglipron, with its sources](https://pepvault.app/peptides/orforglipron#weeks)

## With this comparison

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1](https://pepvault.app/research/retatrutide-triumph-1-2026)
- [All 12 studies](https://pepvault.app/research#retatrutide)
- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Titration](https://pepvault.app/glossary/titration)
- [Bioavailability](https://pepvault.app/glossary/bioavailability)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)

## Questions people ask

### How long do retatrutide and orforglipron last?

The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets).

### How often are retatrutide and orforglipron taken?

Retatrutide: weekly. Route: SubQ injection. Orforglipron: daily. Route: Oral tablet.

### How are retatrutide and orforglipron dosed in research?

The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. Studied in research — not a recommendation. The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose.

### What are the common side effects of retatrutide and orforglipron?

For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For orforglipron: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping.

## Each one in full

- [Retatrutide: dosage, half-life & reference guide](https://pepvault.app/peptides/retatrutide)
- [Orforglipron: dosage, half-life & reference guide](https://pepvault.app/peptides/orforglipron)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking retatrutide or orforglipron? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking retatrutide or orforglipron? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1](https://pepvault.app/research/retatrutide-triumph-1-2026)
- [All 12 studies](https://pepvault.app/research#retatrutide)
- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Titration](https://pepvault.app/glossary/titration)
- [Bioavailability](https://pepvault.app/glossary/bioavailability)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)

<!--promo-->

PepVault for iPhone

## Taking retatrutide or orforglipron? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
